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Aims The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complica-
tions in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with
ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Methods The associations between sex subgroup and the primary composite outcomes, secondary outcomes, and major bleeding
endpoints as well as interaction of sex subgroup with treatment effects were analysed using Cox proportional-hazards
models.
Results Sex was not significantly associated with the probability of the primary composite endpoint [adjusted hazard ratio (HR):
1.02 (0.9121.16)], or other adverse cardiovascular endpoints. Ticagrelor was similarly more effective than clopidogrel in
reducing rates of the primary endpoint in women 11.2 vs. 13.2% [adjusted HR: 0.88 (0.7421.06)] and men 9.4 vs. 11.1%
[adjusted HR: 0.86 (0.7620.97)] (interaction P-value 0.78), all-cause death in women 5.8 vs. 6.8% [adjusted HR: 0.90
(0.6921.16)] and men 4.0 vs. 5.7% [adjusted HR: 0.80 (0.6720.96)] (interaction P-value 0.49), and definite stent throm-
bosis in women 1.2 vs. 1.4% [adjusted HR: 0.71 (0.3621.38)] and men 1.4 vs. 2.1% [adjusted HR: 0.63 (0.4520.89)] (inter-
action P-value 0.78). The treatments did not differ for PLATO-defined overall major bleeding complications in women
[adjusted HR: 1.01 (0.8321.23)] or men [adjusted HR: 1.10 (0.9821.24)]. Sex had no significant association with
these outcomes (interactions P ¼ 0.4320.88).
Conclusion Female sex is not an independent risk factor for adverse clinical outcomes in moderate-to-high risk ACS patients.
Ticagrelor has a similar efficacy and safety profile in men and women.
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Introduction
Women who present with acute coronary syndrome (ACS) are typ-
ically older than men, and have a higher frequency of concomitant
hypertension or diabetes mellitus, and less often a history of myocar-
dial infarction (MI).1 –12 Studies suggest that the treatment and
approach of ACS also differs between women and men, including
the use of effective short-term medication (as thrombolytics), long-
term medication, do-not-resuscitate orders, and invasive proce-
dures.1,3,5– 9,13
A number of reports indicated no significant differences between
sexes for in-hospital or 30-day mortality, after adjustment for base-
line characteristics.4– 6,8 –11,14 Also regarding long-term mortality
rates, adjusted data in several reports suggest no difference
between the sexes.1,2,6,9 However, the Register of Information and
Knowledge About Swedish Heart Intensive Care Admissions
(RIKS-HIA) study reported lower all-cause mortality in women at 1
year, after adjustment for age.10
Ticagrelor is a reversibly binding, oral P2Y12 receptor antagonist.
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It has been approved in .90 countries for preventing thrombotic
events in patients with ACS.16,17 In the phase III PLATelet inhibition
and patient Outcomes (PLATO) trial, ticagrelor significantly
reduced the composite rate of death from cardiovascular causes
(CV death), MI, or stroke at 12 months, without increasing the rate
of PLATO-defined overall major bleeding, compared with clopido-
grel in patients with ACS with or without ST-segment elevation.18
Given the potential importance of sex on treatment approach and
outcome in patients with ACS, we present a pre-specified analysis of
the association between sex and the effects of ticagrelor vs. clopido-
grel on clinical outcomes and treatment-related complications




PLATO wasan international, multicentre, randomized, double-blind trial.
The methodology of PLATO (including study design, inclusion and exclu-
sion criteria, patients and outcome variables) has been published previ-
ously.18,19 In brief, 18 624 patients hospitalized for ACS, with or
without ST segment elevation, were randomized to receive ticagrelor
or clopidogrel in a double-blind, double-dummy manner within 24 h of
the most recent cardiac ischaemic symptoms and before any planned
or urgent percutaneous coronary intervention (PCI).
Ticagrelor was administered as a loading dose of 180 mg followed by
90 mg twice daily. Clopidogrel was administered as a maintenance
dose of 75 mg daily, preceded by a loading dose of 300 mg in patients
who had not received an open-label loading dose and had not received
clopidogrel for ≥5 days before randomization. Before PCI procedures,
a further 300 mg clopidogrel dose (or ticagrelor 90 mg in the case of
PCI procedures later than 24 h after randomization) was permitted at
the discretion of the investigator. The assigned study treatment was con-
tinued for at least 6 months and up to a maximum of 12 months. All the
patients also received acetylsalicylic acid (aspirin) 75–100 mg/day unless
they were known to be aspirin intolerant. For patients who previously
had not received aspirin, the preferred loading dose was a maximum of
325 mg. After stent placement, an aspirin dose of up to 325 mg/day for
6 months was permitted.
The primary efficacy endpoint was the composite of time to first oc-
currence of MI, stroke, or CV death, and the primary safety endpoint
was time to PLATO-defined and adjudicated first major bleeding event.19
The study adhered fully to the ethical principles of the Declaration of
Helsinki, the research protocol was approved by all appropriate locally
appointed ethics committees, and informed consent was obtained
from the patients.18,19
Statistical analysis
Patient characteristics were compared according to sex using x2 and
Wilcoxon rank-sum tests. Cox proportional-hazards models were
used to analyse the association between sex subgroup and the primary
composite endpoint and each of the secondary endpoints and major
bleeding endpoints.
Adjustment variables besides geographic region also included age,
weight, height, body mass index, waist circumference, heart rate, systolic
blood pressure, smoking status, white blood cell count, haemoglobin
level, creatinine clearance, troponin level, time from onset of symptoms
to randomization, changes in electrocardiogram (ECG) at entry
(ST-elevation or ST-depression), Killip class at entry, glycoprotein inhibi-
tors (GPIs) at entry, prior MI, prior stroke, prior transient ischaemic
attack (TIA), prior PCI, prior coronary artery bypass grafting (CABG),
prior gastrointestinal bleeding episodes, diabetes, peripheral arterial
disease (PAD), dyslipidaemia, angina pectoris, congestive heart failure,
final diagnosis, randomized treatment, and treatment approach.
The interaction of sex subgroup with treatment effects was investi-
gatedbyuseof Coxproportional-hazards models. Forefficacyendpoints,
all analyses were based on the intent-to-treat approach. Bleeding end-
points were analysed up to 7 days after permanent discontinuation, and
only in patients who had received at least one dose of the study drug.
Dyspnoea rates by gender and randomized treatment at 1 year were esti-
mated using the Kaplan–Meier (KM) method. Hazard ratios (HR) com-
paring the randomized treatments and the treatment by gender
interaction test were derived using a Cox regression model.
The proportional hazard assumption was assessed using the method
proposed by Lin et al.20 based on the cumulative sum of martingale resi-
duals. For the endpoints where the proportional hazard assumption was
not met, a piecewise proportional hazard model was used. The cutpoints
for the piecewise segments were selected using likelihood ratio tests.
Ventricular pauses by gender and treatment at first week and 30 days
were summarized as percentages. Odds ratios comparing randomized
treatments and the treatment by gender interaction were derived using
a logistic regression model.
All the analyseswereperformed usingSASw, version 9.2 (SAS Institute,
Gary, NC, USA). Comparisons forexploratoryanalyses used a two-sided
significance level of 0.05 without correction for multiple comparisons.
Results
Baseline characteristics
Baseline characteristics of the study population are presented in
Table 1, stratified by sex. Fewer women than men were randomized
in the PLATO trial, with the study population comprising 28.4%
women (5288/18 624); percentage of women was approximately
uniform across regions (data not shown). Therewasno significant dif-
ference in the allocation of randomized treatments between sexes.
Baseline characteristics of women randomized to the two arms of
the study are presented in Supplementary material online, Table S1B.
In terms of CV risk factors, age ≥75 years, dyslipidaemia, and
hypertension were more frequent in women compared with men,
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Table 1 Patient baseline characteristics, final diagnosis, and management
Characteristic Women (n 5 5288) Men (n5 13 336) P-value
Weight and BMI
Median body weight, kg (25th–75th percentile) 71 (62–81) 82 (73–92) ,0.0001
Body weight ,60 kg, % (n) 16.7 (878) 3.3 (434) ,0.0001
Median BMI, kg/m2 (25th–75th percentile) 27.5 (24.4–31.1) 27.4 (24.8–30.2) 0.1040
Age ≥75 years 23.7 (1251) 12.2 (1627) ,0.0001
Habitual smoker 23.1 (1221) 41.0 (5457) ,0.0001
Hypertension 76.8 (4058) 61.0 (8125) ,0.0001
Dyslipidaemia, including hypercholesterolaemia 48.2 (2547) 46.1 (6142) 0.0090
Angina pectoris 48.6 (2568) 43.4 (5790) ,0.0001
Myocardial infarction 17.8 (940) 21.6 (2884) ,0.0001
Congestive heart failure 8.2 (431) 4.6 (619) ,0.0001
PCI 10.9 (575) 14.4 (1917) ,0.0001
CABG 4.2 (221) 6.6 (885) ,0.0001
TIA 3.2 (169) 2.5 (330) 0.0059
Non-haemorrhagic stroke 4.6 (243) 3.6 (479) 0.0014
PAD 5.4 (287) 6.4 (857) 0.0106
Chronic renal disease 4.7 (247) 4.0 (538) 0.0508
Baseline laboratory values, median (25th–75th percentile)
Glucose, mmol/L 7.0 (5.8–9.2) 6.8 (5.7–8.7) ,0.0001
HbA1c, % 6.1 (5.7–6.9) 5.9 (5.6–6.5) ,0.0001
EGFR, mL/min/1.73 m2 74 (59–89) 86 (71–01) ,0.0001
Final diagnosis, % (n)
STEMI 30.6 (1613) 40.7 (5413) ,0.0001
NSTEMI 43.0 (2266) 42.8 (5689)
Unstable angina 22.8 (1202) 14.3 (1910)
Other 3.6 (192) 2.2 (297)
Pre-randomization management strategy
Planned invasive, % (n) 64.0 (3382) 75.2 (10 026) ,0.0001
Randomized to ticagrelor, % (n) 50.2 (2655) 50.1 (6678) 0.8699
Procedures during study
PCI before discharge 51.0 (2698) 65.0 (8665) ,0.0001
PCI during study 54.1 (2859) 68.4 (9119) ,0.0001
Coronary angiography before discharge 74.4 (3935) 84.3 (11 235) ,0.0001
Coronary angiography during study 79.2 (4187) 88.4 (11 793) ,0.0001
CABG before discharge 4.0 (211) 5.7 (759) ,0.0001
CABG during study 7.8 (411) 11.2 (1488) ,0.0001
Concomitant medication taken during study, % (n)
Aspirin 95.8 (5062) 96.5 (12 852) 0.0317
b-Blockers 85.3 (4505) 85.5 (11 390) 0.6918
ACE and/or angiotensin II inhibitors 87.1 (4598) 85.3 (11 363) 0.0022
Statins 91.6 (4838) 94.8 (12 622) ,0.0001
Calcium channel inhibitors 29.6 (1565) 21.7 (2893) ,0.0001
Diuretics 49.4 (2607) 38.3 (5100) ,0.0001
x2 and Wilcoxon rank-sum tests were used for comparisons between sexes. No adjustments were made for multiple testing.
ACE, angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; EGFR, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin;
NSTEMI, non-ST-elevationmyocardial infarction; PAD,peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction;TIA, transient
ischaemic attack
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whereas men more frequently reported habitual smoking. More
women had a previous history of angina pectoris, chronic heart
failure, TIA or non-haemorrhagic stroke, and more men had previ-
ously had manifestations of PAD, MI, PCI, or CABG. Median serum
glucose and glycosylated haemoglobin (HbA1c) levels were higher
in women than in men. The median estimated glomerular filtration
rate was higher in men. Following study entry, women more fre-
quently had a final diagnosis of unstable angina than men, but had
fewer final diagnoses of ST-elevation myocardial infarction
(STEMI). Planned and received procedures, including CABG, were
more frequent in men.
Association between sex and outcomes,
independent of randomized treatment
In the overall population, female sex was not significantly associated
with the risk of the primary composite endpoint [adjusted HR: 1.02
(0.9121.16); Figure 1]. Female sex was also not significantly asso-
ciated with all-cause death [adjusted HR: 0.86 (0.7321.02)], inci-
dence of stent thrombosis [adjusted HR: 0.81 (0.5621.18)], or
other efficacy endpoints. Unadjusted data for efficacy endpoints in
females and males are described in Supplementary material online,
Table S2A.
Regarding safety endpoints, rates of non-CABG-related major
bleeding did not differ significantly between sexes [adjusted HR:
1.16 (0.9621.40)], but women experienced a lower rate of
CABG-related major bleeding events [adjusted HR: 0.57
(0.4920.67)]. PLATO-defined and adjudicated overall major bleed-
ing rate was lower in women than in men [adjusted HR: 0.81
(0.7120.92)], but this difference may be explained by the lower
CABG-related bleeding rate and less use of CABG in women.
When major and minor bleeding were combined, there was still sig-
nificantly less bleeding in women compared with men (Figure 1).
The same was true for any bleeding including major, minor, and
minimal bleeding (Figure 1). Age and body mass index were univari-
ately associated with major bleeding but the association of body
mass index disappeared when adjusted by age. Women were
more likely to have low body mass index than men (data not
shown). Unadjusted data describing the association of gender
Figure1 Association between sex and clinical outcome. *n ¼ 5288. †n ¼ 13 336. ‡Adjustment variables selected from the following: age, weight,
height, body mass index, waist circumference, race, smoking status, diabetes, hypertension, heart rate, systolic blood pressure, changes in electro-
cardiogram at entry, electrocardiogram depression, killip class at entry, age, haemoglobin, white blood cells, dyslipidaemia, creatinine, angina pec-
toris, prior myocardial infarction, congestive heart failure, prior GI bleeding, prior percutaneous coronary intervention, prior coronaryartery bypass
grafting, prior transient ischaemic attack, prior non-haemorrhagic stroke, peripheral arterial disease, renal disease, chronic obstructive pulmonary
disease, final diagnosis, onset of symptoms to randomized treatment, glycoprotein IIb/IIIa inhibitors at randomization, randomized treatment, treat-
ment approach, and region. §PLATO-defined and adjudicated19. ††Any bleeding includes major, minor, and minimal bleedings. CABG, coronary
artery bypass grafting; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV death, death from cardiovascular causes; ECG,
electrocardiogram; GI, gastrointestinal bleeding; HR, hazard ratio; KM, Kaplan–Meier analysis; MI, myocardial infarction; PAD, peripheral artery
disease; PCI, percutaneous coronary intervention; TIA, transient ischaemic stroke.
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with endpoints are provided in Supplementary material online,
Table S2A.
Association between sex and efficacy
of randomized treatment
When the association of sex with outcomes was assessed by rando-
mized treatment, ticagrelor was associated with similar reductions
among women and men in CV death, MI, or stroke [women: adjusted
HR: 0.88 (0.74–1.06); men: adjusted HR: 0.86 (0.76–0.97); Figures 2
and 3]; all-cause death [women: adjusted HR: 0.90 (0.69–1.16); men:
adjusted HR: 0.80 (0.67–0.96) Figures 2 and 4]; and definite stent
thrombosis [women: adjusted HR: 0.71 (0.36–1.38); men: adjusted
HR: 0.63 (0.45–0.89)] compared with clopidogrel. For these out-
comes, the interaction between randomized treatment and sex
remained non-significant (interaction range P ¼ 0.4920.78). Supple-
mentary material online, Table S3A presents unadjusted data.
Further analyses of the associations between sex, randomized
treatment, and either final diagnosis (STEMI vs. NSTEMI, unstable
angina or ‘other’) or planned treatment (invasive vs. medically
managed) revealed no significant interactions for studied endpoints
(interaction P-value range 0.2020.83).
Association between sex and safety
of randomized treatment
There were no differences between ticagrelor and clopidogrel for
PLATO-defined overall major bleeding episodes either in women
[adjusted HR: 1.01 (0.8321.23)] or men [adjusted HR: 1.10
(0.9821.24); Figures 2 and 5]. There was no evidence of randomized
treatment by sex interaction for this outcome (P ¼ 0.43) Unadjusted
data are presented in Supplementary material online, Table S3B. No
differences in majoror minor bleeding, as well as any bleeding (a com-
posite of major, minor, and minimal bleeding), were observed among
women and men treated with either ticagrelor or clopidogrel
(Figure 2).
Consistentwith the main studydata, ticagrelor wasassociated with
an increase in non-CABG-related major bleeding when compared
with clopidogrel in both women [adjusted HR: 1.19 (0.9021.56)]
and men [adjusted HR: 1.37 (1.1021.72); Figure 2]. There was no sig-
nificant interaction between treatment and sex (P ¼ 0.42; Figure 2).
Additional analyses of the associations between sex, randomized
treatment, and either final diagnosis or planned treatment also
revealed no significant interactions for the bleeding endpoints (inter-
action P-value range: 0.1720.67).
Figure 2 Association between sex and treatment, and clinical outcome. *Tic ¼ ticagrelor (n ¼ 9333). †Clop ¼ clopidogrel (n ¼ 9291). ‡Adjust-
ment variables selected from the following: age, weight, waist circumference, smoking status, diabetes, hypertension, heart rate, systolic blood pres-
sure, changes in electrocardiogram at entry, killip class at entry, haemoglobin, white blood cells, dyslipidaemia, angina pectoris, prior myocardial
infarction, congestiveheart failure,priorGIbleeding, priorpercutaneouscoronary intervention, priorcoronaryarterybypass grafting, prior transient
ischaemic attack, non-haemorrhagic stroke, peripheral arterial disease, chronic renal disease, chronic obstructive pulmonary disease, final diagnosis,
onset of symptoms to randomized treatment, GP Iib/IIIa inhibitors at randomization, randomized treatment, treatment approach, and region.
§PLATO-defined and adjudicated19. ††Any bleeding includes major, minor, and minimal bleedings. CABG, coronary artery bypass grafting; CI, con-
fidence interval; COPD, chronic obstructive pulmonary disease; CV death, death from cardiovascular causes; ECG, electrocardiogram; GI, gastro-
intestinal bleeding; HR, hazard ratio; KM, Kaplan–Meier analysis; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient
ischaemic stroke.
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Figure3 Cumulative Kaplan–Meier estimates of the incidence of the primary composite outcome—cardiovascular death/myocardial infarction/
stroke, bysexand treatment (ticagrelor vs. clopidogrel). Estimated event rateat12 months, ticagrelor vs. clopidogrel, interactionP ¼ 0.88.CV death,
death from cardiovascular causes; MI, myocardial infarction.
Figure 4 Cumulative Kaplan–Meier estimates of incidence of all-cause death, by sex and treatment (ticagrelor vs. clopidogrel). Estimated event
rate at 12 months ticagrelor vs. clopidogrel, interaction P ¼ 0.50.
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Higher rates of dyspnoea were reported during ticagrelor treat-
ment than with clopidogrel treatment in both women [16.3 vs.
9.0%; HR: 1.86 (1.5822.20)] and men [KM estimate at 1 year: 14.2
vs. 8.3%; HR: 1.81 (1.6222.01); Table 2]. Ventricular pauses were
more frequent in patients receiving ticagrelor compared with those
receiving clopidogrel; however, a significant difference in rates was
only observed for pauses of ≥3 s during the first week in men [6.0
vs. 3.7%; HR: 1.64 (1.0922.47)]. There was no evidence of inter-
action between randomized treatment and sex for dyspnoea and
ventricular pauses (interaction P-value range: 0.3420.89).
Discussion
The results of the present adjusted analysis largely correspond with
those reported for the large registry studies, in that men and
women with ACS encounter similar mortality.1,2,6,9
In the present study, unadjusted data showed a significantly higher
incidence of the efficacy endpoints of CV death, myocardial infarc-
tion, or stroke (individually and in combination) in women;
however, this difference disappeared after adjustment for baseline
characteristics including age.
Women with ACS have been reported to have a higher risk of
bleeding complications than men.21 The suggested important risk
factors for bleeds have included a smaller body and vessel size,
older age, reduced creatinine clearance, higher prevalence of co-
morbidities, higher rate of overdosed antithrombotic medication,
and differences in response to antithrombotics between women
and men.21 In the present study, unadjusted data showed no
differences in bleeding risk between men and women. However,
after adjustment for various baseline characteristics, including age,
women had significantly fewer major, major or minor, and any bleed-
ing events.
In the present analysis, the rate of overall major bleeding events
appeared lower in women than men contrary to previous evi-
dence.21 –23 However, it is likely that this observation mainly reflects
the significantly lesser use of CABG surgery and the lower rate of
CABG-related major bleeding in women in the PLATO trial. Thus
the non-CABG-related bleeding rates in the present study were
not different between women when compared with men. This
difference from the previously reported figures may be due to the
careful registration of and adjustment for differences in baseline
characteristics.
This analysis of the effect of female sex on outcomes related to
treatment with ticagrelor and clopidogrel in ACS patients reveals
results that are consistent with those reported for the primary
study outcomes.18 This is true for both unadjusted and adjusted
data. Both in women and men with ACS, ticagrelor reduced the
rates of adverse CV events and mortality compared with clopidogrel,
without an increase in the rate of PLATO-defined overall bleeding.
In both sexes, however, and in agreement with the main study
results, there was a similar increase in the rate of non-CABG-related
major bleeding complications in the ticagrelor-treated patients. This
finding was consistent for both unadjusted and adjusted data.
With regard to other phase III studies, the Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction
Figure 5 Cumulative Kaplan–Meier estimates of incidence of overall major bleeding complications (PLATO-defined), by sex and treatment
(ticagrelor vs. clopidogrel). Estimated event rate at 12 months ticagrelor vs. clopidogrel, interaction P ¼ 0.43. CABG, coronary artery bypass.
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(TRITON-TIMI38) studyreportedsimilarefficacy forprasugrel inmen
(risk reduction in CV death, non-fatal MI, or non-fatal stroke ¼ 21%)
and the overall study population (risk reduction ¼ 19%).24 In the
TRITON-TIMI 38 study, 26% of the patients were women and com-
pared with men they were older, lighter in body weight, more often
had diabetes mellitus, hypertension, and renal impairment, but less
often had prior MI and tobacco use.25 Rate of CV death was higher
for women than men (2.9 vs. 2.0%; P ¼ 0.01), but the difference
disappeared after adjustment for baseline differences that included
age [HR: 1.08 (0.80–1.46)]. Non-CABG TIMI major bleeding events
occurred more frequently in women than in men, but after adjustment
the difference disappeared [HR: 1.20 (0.90–1.61)]. However, the
incidence of non-CABG TIMI minor bleeding was significantly higher
in women before and after adjustment [HR: 2.15 (1.66–2.80)]. Sex
and management with prasugrel and clopidogrel did not interact for
CV death and major bleeding complications.
A numerically lower absolute reduction in efficacy endpoints was
reported for women receiving clopidogrel in the Clopidogrel in Un-
stable Angina to Prevent Recurrent Events (CURE) study, but the dif-
ference was not significant.26 A meta-analysis of blinded randomized
trials comparing clopidogrel and placebo (including CURE, CREDO,
CLARITY-TIMI 28, COMMIT, and CHARISMA) reported no signifi-
cant difference in treatment effect between men and women.27
A meta-analysis on early invasive therapy vs. conservative treat-
ment strategies in women and men with non-ST-elevation ACS
(NSTE-ACS) demonstrated a comparable benefit of invasive
therapy in men and high-risk women, with positive cardiac bio-
markers without benefits in the low-risk women.28 Similarly, the
benefit of GPI in women with NSTE-ACS in contrast to men was
restricted to the patients with a positive troponin concentration.29
In a separate pre-planned analysis of PLATO data, the effect and
treatment-related complications of ticagrelor vs. clopidogrel in
patients aged ≥75 years were compared with those aged ,75
years.30 The clinical benefit of ticagrelor over clopidogrel (with
regard to the primary composite endpoint, definite stent thrombosis,
or all-cause death), or PLATO-defined overall major bleeds, did not
differ significantly between the agegroupsafteradjustmentofdata for
important differences in baseline characteristics including sex.
Study limitations
In the present study, comparisons werenot corrected for multiplicity
of analyses. The analyses were therefore susceptible to an increased
type I error and subsequent increase in the likelihood of false-positive
statistical differences. The study was not powered to show gender
differences in efficacy and safety, but with a study population of
18 624 patients, including 5288 (28.4%) women, the total number
of adjudicated events in both men and women were high, with a suit-
able power to show a possible sex-related heterogeneity in observed
event rates.
Conclusion
In aspirin-treated patients with either STEMI managed with primary
PCI, or NSTE-ACS, there were no differences between women
and men for adverse clinical outcomes or concerning efficacy or
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 The incidence of dyspnoea and ventricular pauses by sex and treatment
Ticagrelor Clopidogrel Interaction
P-value
Dyspnoea KM % (n) KM % (n) HR (95% CI)
Women 16.3 (389) 9.0 (214) 1.86 (1.58–2.20) 0.7610
Men 14.2 (870) 8.3 (500) 1.81 (1.62–2.01)
Ventricular pauses % (n/N) % (n/N) OR (95% CI)
First week
≥3 s
Women 5.2 (20/386) 3.4 (13/381) 1.55 (0.76–3.16) 0.8860
Men 6.0 (64/1075) 3.7 (39/1051) 1.64 (1.09–2.47)
≥5 s
Women 1.3 (5/386) 1.3 (5/381) 0.99 (0.28–3.44) 0.3408
Men 2.2 (24/1075) 1.1 (12/1051) 1.98 (0.98–3.97)
At 30 days
≥3 s
Women 1.2 (3/249) 1.1 (3/265) 1.07 (0.21–5.33) 0.8241
Men 2.4 (18/743) 1.9 (14/747) 1.30 (0.64–2.63)
≥5 s
Women 0.4 (1/249) 0.4 (1/265) 1.07 (0.07–17.1) 0.8541
Men 0.9 (7/743) 0.7 (5/747) 1.41 (0.45–4.47)
CI, confidence interval; HR, hazard ratio; KM, Kaplan–Meier analysis; OR, odds ratio.
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safety outcomes of treatment with ticagrelor compared with
clopidogrel.
Supplementary material
Supplementary material is available at European Heart Journal online.
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